Answers are grounded in this paper and cite their sources.
The analytical validation presented here contributed to the ReEBOV RDT being the first antigen-based assay to receive FDA and World Health Organization emergency use authorization for this EVD outbreak, in February 2015.
No takes yet. Share an insight, caveat, or question.
Cross et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: